RenovoRx Revenue Jumps 28 Percent in Q2

RenovoRx (NASDAQ:RNXT), a medical technology company focused on targeted cancer therapy delivery, reported earnings on August 14, 2025. As sales of its RenovoCath device grew to $422,000 (GAAP), surpassing the analyst consensus of $329,633 (GAAP) by 28.0%. Earnings per share (EPS) (GAAP) also landed better than expected, at a net loss of ($0.08) compared to the estimated loss of ($0.085). While the company posted a larger net loss (GAAP) than the prior year, overall results show commercial momentum in both sales and new cancer center approvals. Despite ongoing losses, the quarter highlighted emerging commercial traction and progress in its pivotal Phase III TIGeR-PaC trial. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. RenovoRx is advancing precision oncology through targeted delivery of chemotherapy and other therapies directly to solid tumors. Its flagship product, the RenovoCath medical device, enables the targeted delivery of chemotherapy via blood vessels at the tumor site. The company's core focus is improving outcomes for difficult-to-treat cancers with reduced side effects, primarily through its Trans-Arterial Micro-Perfusion (TAMP) therapy platform.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool